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Background: Most older adults want to live independently in a familiar environment instead of moving to a
nursing home. Preventive home visits based on multidimensional geriatric assessment can be one strategy to
support this preference and might additionally reduce health care costs, due to the avoidance of costly nursing
home admissions. The purpose of this study was to analyse the cost-effectiveness of preventive home visits from a
societal perspective in Germany.
Methods: This study is part of a multi-centre, non-blinded, randomised controlled trial aiming at the reduction
of nursing home admissions. Participants were older than 80 years and living at home. Up to three home visits
were conducted to identify self-care deficits and risk factors, to present recommendations and to implement
solutions. The control group received usual care. A cost-utility analysis using quality-adjusted life years (QALY)
based on the EQ-5D was performed. Resource utilization was assessed by means of the interview version of a
patient questionnaire. A cost-effectiveness acceptability curve controlled for prognostic variables was constructed and
a sensitivity analysis to control for the influence of the mode of QALY calculation was performed.
Results: 278 individuals (intervention group: 133; control group: 145) were included in the analysis. During 18 months
follow-up mean adjusted total cost (mean: +4,401 EUR; bootstrapped standard error: 3,019.61 EUR) and number of
QALY (mean: 0.0061 QALY; bootstrapped standard error: 0.0388 QALY) were higher in the intervention group, but
differences were not significant. For preventive home visits the probability of an incremental cost-effectiveness
ratio <50,000 EUR per QALY was only 15%. The results were robust with respect to the mode of QALY calculation.
Conclusions: The evaluated preventive home visits programme is unlikely to be cost-effective.
Trial registration: Clinical Trials.gov Identifier: NCT00644826.
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80 years and over, Quality-adjusted life yearsBackground
Due to demographic change the group of older adults in
Germany and most other European countries will in-
crease substantially within the coming decades [1]. Most
older adults prefer to grow old in the community within
a familiar environment instead of moving to a nursing
home. Preventive home visits based on multidimensional
geriatric assessment can be one measure to support this* Correspondence: c.brettschneider@uke.de
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article, unless otherwise stated.preference and might additionally reduce health care
costs, due to the avoidance of costly nursing home
admissions. However, compared to single interventions
in community-dwelling populations like fall prevention
programs [2,3], the effectiveness of preventive home
visits remains uncertain [4-8]. In their systematic review
Huss et al. concluded that multidimensional preventive
home visits have the potential to reduce disability burden
[8]. However, effects on nursing home admissions were
heterogeneous. Huss et al. explained these variations be-
tween studies by means of four major factors: intervention
program characteristics, population characteristics, adher-
ence to recommendations made by the program and theCentral. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Brettschneider et al. BMC Health Services Research  (2015) 15:141 Page 2 of 11specific setting [8]. Besides the vast literature on the
effectiveness, there are only a few studies on the cost-
effectiveness of preventive home visits, using different
outcome measures like active life-years gained or success-
ful treatment [9-13], but neglecting the effects on health-
related quality of life. Furthermore, to our knowledge no
study has assessed resource use associated with informal
care which - from a societal perspective – is a major cost
category in populations of older aduts [14].
To measure the impact of preventive home visits on
health-related quality of life and to enable comparison
with other (preventive) interventions for other conditions,
cost-utility analyses can be conducted. Internationally,
only one cost-utility analysis of preventive home visits in
Sweden has been conducted so far [11]. However, health-
related quality of life was only measured post hoc.
The purpose of this study was to perform a cost-utility




This study is part of a 18-month multi-centre, non-
blinded, randomised controlled trial focusing on the ef-
fectiveness of preventive home visits in terms of reduction
of nursing home admissions (primary endpoint) (Clinical
Trials.gov Identifier: NCT00644826). The methods have
been described in detail elsewhere [15,16]. In brief, study
participants were recruited in two regions of Eastern
Germany (Halle and Leipzig) via GP practices (in both
regions), hospitals and the registration offices (only in
Halle). Individuals were recruited between August 2007
and July 2008. Participants had to be older than 80 years,
residents of Leipzig or Halle, and had to live at home or –
in case of hospital patients – discharge to home had to be
planned already. Individuals were excluded if they had in-
sufficient German language skills, suffered from cognitive
impairment, were not able to give informed consent or
had a care level >1 (according to German long term care
insurance [17]). This means that patients were excluded if
they needed assistance in more than two activities of basic
nursing (e.g. personal hygiene, feeding, mobility) more
than once a day. To be eligible for care level 1 the max-
imum amount of care must not exceed 3 hours a day.
Participants were randomised to intervention and con-
trol group using a balanced block-wise randomisation
stratified by region. The sample size required to detect a
reduction of nursing home admissions from 20% to 7%
with 80% power at a significance level of 5% assuming a
drop-out rate of 30% was calculated to be n = 320 [15].
In total n = 336 adults older than 80 years gave informed
consent to participate in the study and were screened
for eligibility. 31 participants were not eligible. 305 older
adults were randomised. N = 150 received the interventionand n = 155 received usual care. One further patient of the
IG was excluded from the analysis ex post. This patient
was not part of the target population of the intervention
as he received 24 hour professional care at home and was
unable to live independent in his or her own home.
Finally, n = 304 patients were part of this analysis (Figure 1).
The time horizon of the RCT was 18 months.
Intervention
In the intervention group (IG) a multidimensional geri-
atric assessment was performed by trained personnel
(nursing scientist, psychologist or sociologist) in a first
preventive home visit. In this first visit the current nutri-
tion status, the impairment of sight and hearing, urinary
and bowel incontinence and the loss of functional
muscle mass was assessed. Furthermore social activities,
housing conditions, economic conditions, polypharmacy
and the cognitive status were determined.
A case conference was conducted by a multi-professional
team (nursing scientist, psychologist, geronto-psychiatrist,
nutritionist, social worker) within three weeks after the
geriatric assessment to work out individualized recommen-
dations based on an analysis of identified self-care deficits
and risk factors for institutionalization.
After the case conference the participants of the IG
were visited again for the second preventive home visit
by the personnel who performed the first visit. The vis-
itor reported to the participant on identified self-care
deficits and risk factors and presented the results and
recommendations of the case conference.
Four weeks after the second visit the third preventive
home visit was arranged. In this visit, also called booster
session, the adherence to the recommendations was
evaluated. Furthermore, obstacles and facilitators of
adherence were identified, the recommendations were
reviewed, and further support was offered. The re-
searchers were not involved in carrying out the
intervention.
The control group (CG) received usual care (i.e. every
service offered by the statutory health insurance system
and utilized by the patient on his own initiative).
Data collection and measures
Data collection
The data collection process has been described in detail
elsewhere [15]. In brief, all study participants at baseline
(2007/2008) and follow-up (18 months) were inter-
viewed face-to-face by skilled and trained staff of the
two study centres.
Besides the geriatric assessments, data on socio-
demography (age, gender, living situation, and educa-
tion), basic activities of daily living (Barthel Index [18]),
instrumental activities of daily living (IADL by Lawton
and Brody [19]), cognitive status (Mini Mental State
Figure 1 Flow chart of patient inclusion and exclusion.
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(Geriatric Depression Scale (GDS) [21]) as well as
health-related quality of life (EQ-5D), service use and
patient costs were collected.
In a few cases where a face-to-face interview at follow-
up was declined, telephone interviews with the respondent
or proxy interviews (e.g. family member) were offered.
In addition, if a respondent developed a cognitive im-
pairment during follow-up proxy interviews were also
conducted.
Drop-out rates were rather low, resulting in n = 133
(89%) participants analysed in the IG and n = 145 (94%)
in the CG (Figure 1). Drop-outs were not significantly
different from analysed participants with respect to the
group they were allocated to (χ2-test, p-value = 0.188),
study centre (χ2-test, p-value = 0.847), gender (χ2-test,
p-value = 0.690), and age (t-test, p-value = 0.834). How-
ever, more older adults who were living alone (n = 21)
did not continue the study (χ2-test, p-value = 0.046).
These patients were not different from patients finishing
the study in terms of baseline costs and quality of life.
EQ–5D-3 L
The EQ–5D-3 L is a generic health-related quality of life
(HRQL) questionnaire that comprises five questions(items) relating to current problems in the domains: mo-
bility; self-care; usual activities; pain/discomfort; and
anxiety/depression [22]. Responses in each dimension
are divided into three ordinal levels coded: 1, no prob-
lems; 2, moderate problems; 3, extreme problems. The-
oretically, 35 = 243 different health states can be defined
by the EQ–5D descriptive system.
The EQ–5D also includes a visual analogue scale
(EQ–VAS), similar to a thermometer, ranging from 0
(worst imaginable health state) to 100 (best imaginable
health state) which records the respondent’s self-rated
valuation of health state (EQ–VAS score).
The EQ-5D has been used successfully in the popula-
tions of older adults [23]. Furthermore, according to a par-
ticular set of societal preference values derived from
surveys of the general population, an index score (EQ–5D
index) for each of the 243 EQ–5D health states is available
for various countries, with the best state (perfect health)
and ‘death’ being assigned values of one and zero, respect-
ively. In the present study EQ–5D index scores from the
UK [24] were used that were derived from a large general
population sample (n = 2,997). The existing German value
set was not used as it does not consider problems in usual
activities and hence would result in imprecise values [25].
Accordingly, to each participant’s health status on the
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was assigned.
Questionnaire of service utilization and costs
Service use and patient costs for baseline and follow-up
were measured from a societal perspective. The ques-
tionnaire was based on service use questionnaires used
in earlier studies [26-29], which were adapted to the pur-
poses of the present study, and the German adaptation
of the Resource Utilisation in Dementia (RUD) question-
naire [30] to assess informal care. Informal care was
assessed by two questions focussing on time spent on
assistance in basic activities of daily living (e.g. toilet use,
dressing, bathing) and in instrumental activities of daily
living (e.g. cooking, support in financial issues, shopping,
housekeeping).
To minimize recall bias resource utilisation was
assessed retrospectively over different time periods. For-
mal and informal nursing care, outpatient physician ser-
vices, pharmaceuticals, use of outpatient non-physician
services (e.g. occupational therapy, physiotherapy, logo-
pedics, sports therapy) medical supply and dentures as
well as transportation to and from medical treatments
were assessed over 3 months. Inpatient services were re-
corded during the last 12 months and costs for in-home
modifications during the past 18 months. Depending on
the service, quantity of use or duration was recorded
(Table 1). To further account for recall bias, lists of pos-
sible services were presented (e.g., every outpatient ser-
vice was addressed specifically in the questionnaire).
Indirect costs due to productivity losses with respect to
paid and unpaid work and reduced productivity were
not included, since they are of minor importance in this
older population.Table 1 Resources and unit costs used for cost calculation
Sector Service/goods
Nursing care Formal care Nursing home
Ambulatory c
Informal care
Inpatient services Acute hospital and hospitals for rehab
Medication Product
Outpatient physician services GP, specialists (e.g. cardiologist, intern
ophthalmologist)
Outpatient non-physician services e.g. physiotherapy, massage, lymph d
ergotherapy
Medical devices and dentures Product
Transportation Transportation by car, public transpor
ambulance
GP = General practitioner; km = kilometer.Unit costs
To determine direct health care costs, unit costs were
calculated for all services used and for all goods privately
purchased or prescribed. Costs were determined for the
different time periods of resource utilisation and then
extrapolated to 18 months by multiplying them by 6 (in
case of 3-month assessment) or 1.5 (in case of 12-month
assessment), respectively. Costs were calculated in EUR
at 2008 price level. If unit cost data was only available
for years before 2008, costs were inflated using the
consumer price index [31]. Costs were not discounted
because of the short time horizon of 18 month.
Detailed information regarding monetary valuation is
shown in Table 1. In brief, nursing home care was val-
ued using calculated costs of care per day, differentiated
by the level of care [32] and market prices for assisted
living. Professional nursing care was valued using the
average hourly gross wage rate plus non-wage labour
costs for employees in the domain of care and assistance
for the older adults or handicapped (18.69 EUR per
hour) [33,34]. Informal care was valued using the re-
placement cost method, i.e. it was assumed that informal
care could have been substituted by paying a profes-
sional caregiver, and hours of informal care were there-
fore valued using the same hourly wage rate as for the
valuation of professional nursing care. For the valuation
of any in-home modifications the self-reported costs
were used.
Inpatient hospital services were valued using average
costs per diem differentiated by the type of the hospital
[35-37]. Costs of outpatient physician services were cal-
culated based average costs per contact [38]. Pharma-
ceuticals were valued based on drug codes, dosage and
duration as recorded in the questionnaire in conjunctionUnits Monetary values (unit costs)
care Days Type specific mean rates by level of
care, market prices [32]
are Hours Type specific wage [33,34]
Hours Type specific wage (replacement cost
approach) [33,34]
ilitation Days Type specific mean rates [35-37]
Quantity Official pharmaceutical index
(Rote Liste) [39]
ist, Contacts Type specific mean rates [38]
rainage, Contacts Reimbursement schedule [40-42]
Quantity Market prices and reimbursement
schedules [38,43,44]
t, taxi or km, quantity Market prices, EUR 0.30 per km for
transport by car [45]
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Outpatient non-physician services were valued using re-
imbursement schemes of the German statutory sickness
funds [40-42]. Costs for medical supply and dentures
were calculated using market prices according to patients’
specifications. If no specification was available reimburse-
ment schemes were used [38,43,44]. Costs for travel on
public transport or by taxi were calculated according to
patients’ specifications. Costs of car travel were calculated
according to the number of kilometres travelled multiplied
by a flat rate of 0.30 EUR per kilometre (according to the
tax-deductible rate allowed for trips to and from work in
Germany, [45]).
Intervention costs
To calculate total costs, intervention costs were added
in the IG to direct health care costs. Intervention costs
consisted of costs for the geriatric assessments, the case
conferences and the following home visits. Furthermore
travel costs to the participants were considered. Cost
calculations were based on recorded staff time and the
number of staff taking part in the case conferences. Staff
time was valued with an average hourly gross wage rate
plus non-wage labour costs for employees as done for
professional nursing services [46,47]. It was assumed
that overhead costs were low because, for example, no
additional room had to be rented and available meeting
rooms were not fully occupied with respect to time.
Data analysis
Calculation of costs
Unadjusted individual total costs Ci at follow-up were
calculated for each participant i. The follow-up period
started with the first home visit. Total costs for each in-
dividual were estimated by summing the 18-month costs
of all costs categories as described above. To take into
account the individual observation time the following
equation for each individual i was used:
Ci ¼ CT1548days days T0;T1ð ÞÞ ð1Þ
where CT1 are the individual total costs measured at
T1 over 18 months (548 days), and days (T0;T1) are the
number of days between the measurement points for the
individual patient.
Participants were excluded, if no information about
costs was retrievable at T1. If the participant had died
during follow-up the cost value for T1 was replaced by
the value of T0 which was adjusted by the individual ob-
servation time. Costs were not discounted.
Calculation of QALY
QALY were calculated by weighting the duration of
health states by the EQ–5D index. Individual QALYi atfollow-up were calculated for each participant i using
linear interpolation between measurement points and
taking into account the individual observation time,
using the following equation:
QALY i ¼ indexT 0 þ indexT12  days T0;T1ð Þ
 
=365 ð2Þ
where indexT0 and indexT1 are the individual EQ–5D
index scores measured at T0 and T1. The procedure to
treat deaths described above for costs was also used for
the computation of QALY: The EQ-5D index for T1 was
replaced by the EQ-5D index for T0 which was multi-
plied by the duration of study participation. QALY were
not discounted.
Statistical analysis
Missing data were rare (0.1% of health economic items
at baseline; 0.3% of health economic items at follow-up)
and were replaced by the unconditional mean of the
respective variable. The level of significance was set at
5%. Differences in means and proportions of baseline
sample characteristics were analysed using t-test with
bootstrapped standard errors (4,000 replications) and
χ2-test, respectively. Differences in mean costs and
mean QALYs between IG and CG were adjusted for
study region, age and gender as well as for baseline
HRQL, 12-month costs at baseline, cognition, basic
and instrumental quality of life and depressive symp-
toms by means of OLS regression with bootstrapped
standard errors.
Net monetary benefit regression with different willingness
to pay thresholds was used to construct cost-effectiveness
acceptability curves (CEAC) controlled for potential prog-
nostic variables [48]. The individual net monetary benefit
(NMBi) was calculated for each participant i as:
NMBi ¼ QALYiWTP−Ci ð3Þ
were QALYi and Ci are the effects and cost for each
participant i, respectively, and WTP is the willingness to
pay for a QALY. We used an ordinary least square
(OLS) regression with bootstrapped standard errors
(4,000 replications) and controlled for study region, age
and gender as well as for baseline HRQL, 12-month
costs at baseline, cognition, basic and instrumental qual-
ity of life and depressive symptoms.
All statistical analyses were carried out on an
intention-to-treat basis using the software package
STATA for Windows, Release 13 (STATA Corp., College
Station, Texas, USA) as well as PASW Statistics 18.0.0
(SPSS Inc., Chicago, IL).
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As stated above we performed a sensitivity analysis based
on the complete sample of 279 patients. Furthermore, to
analyse the sensitivity of the results with respect to the
effect measure, univariate sensitivity analyses were per-
formed. QALY were calculated based on the EQ–5D
index scores derived from a much smaller sample of the
German general population (n = 334) [25] and, alterna-
tively, EQ–VAS scores (divided by 100 for transformation
to a 0–1 scale) were used as QALY weights.
Ethics
The study was approved by the ethics committees of the
universities Halle and Leipzig. Written informed consent
was obtained. All clinical investigations have been con-
ducted according to the principles expressed in the
Declaration of Helsinki. No allowance for the partici-
pation in the study was paid.
Results
Characteristics of the study population at baseline
The characteristics of the study population are presented
in Table 2. There were no significant differences in theTable 2 Comparison of sample characteristics at baseline (n =
Characteristics Intervention group (n = 1
Age (years)
mean (SD) 84.85 (3.54)
Female: n (%) 99 (66.44)
Living situation : n (%)
Alone 94 (63.09)
With spouse/partner 43 (28.86)
With relatives 8 (5.37)
Other 3 (2.01)
Training qualification: n (%)
None 29 (19.46)
Vocational training 93 (62.42)
University 27 (18.12)
Level of care dependency: n (%)
None 122 (81.88)
Level I 25 (16.78)
Level II 2 (1.34)
Level III 0 (0.00)
EQ-5D index
mean (SD) 0.59 (0.28)
EQ VAS
mean (SD) 58.41 (19.27)
18-month costs (€; 2008)
mean (SD) 16,568 (22,221)
*t-test (p-values based on non-parametric bootstrapping (4000 replications)); **Chi2baseline characteristics between the IG and the CG. Re-
spondents had a mean age of 85 years, more women
than men (IG 66%, CG 72%) participated in this study
and the majority of respondents had no level of care in
the long-term care insurance (IG 82%, CG 73%). The
mean EQ-5D index at baseline was not significantly dif-
ferent (IG: 0.59; CG: 0.60), resulting in mean numbers of
QALYs over 18 months at baseline of 0.8907 in the IG
and 0.8954 in the CG, respectively. There was no statis-
tically significant difference in mean 18-months costs
(IG: 16,568 EUR; CG: 18,451 EUR).
Nursing home admissions
As has been reported elsewhere [49] the number of
nursing home admissions (primary endpoint of the trial)
was smaller in the intervention group (n = 8) than in the
control group (n = 15), resulting in an adjusted hazard
ratio (HR) of 0.55 which means that the risk of admis-
sion to nursing home was reduced by 45%. However, this
result was not statistically significant (95%-CI of HR:
0.23 - 1.30). Thus, although the number of nursing
home admissions was reduced the intervention did not
reach its primary goal.304)
























-test; SD: Standard deviation.
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Mean total unadjusted costs in the IG (20,195 EUR)
were 833 EUR lower than in the CG (21,028 EUR)
(Table 3). Yet, total adjusted costs were 4,440 EUR
higher in the IG than in the CG (p = 0.15) (Table 4). In
both groups the most important cost drivers were infor-
mal care (unadjusted 8,802 EUR in IG; 7,434 EUR in
CG) and inpatient hospital care (unadjusted 3,479 EUR
in IG; 3,809 EUR in CG) (Table 3). The high costs of in-
formal care were mainly caused by assistance in instru-
mental activities of daily living (unadjusted 5,951 EUR in
IG; 5,273 EUR in CG). Based on adjusted costs there
were only two statistically significant differences in the
cost categories between IG and CG: The interventionTable 3 Unadjusted costs (by cost category) and QALY at
18-month follow-up





Mean (SD) 20,195 (21,689) 21,028 (24,384)
Intervention costs
Mean (SD) 73 (22) 0 (0)
Inpatient services
Mean (SD) 3,479 (8,183) 3,809 (8,603)
Outpatient services (physician)
Mean (SD) 857 (1,198) 575 (531)
Outpatient services
(non-physician)
Mean (SD) 462 (823) 406 (1,323)
Medication
Mean (SD) 1,385 (1,197) 1,426 (1,462)
Medical devices
Mean (SD) 425 (992) 321 (1,137)
Nursing home care
Mean (SD) 1,228 (5,833) 2,197 (8,519)
Ambulatory care (nursing
service)
Mean (SD) 2,228 (4,280) 1,987 (4,430)
Informal care
Mean (SD) 8,802 (16,714) 7,434 (16,287)
Modification of buildings
Mean (SD) 205 (1,142) 44 (331)
Transportation
Mean (SD) 113 (163) 145 (262)
QALY
Mean (SD) 0.8256 (0.4029) 0.8270 (0.4097)
*Differences from n = 149 and n = 155 owing to missing values, due to
withdrawn consent and no data on service use retrievable; outpatient services
(non-physician) contains: physiotherapy, occupational therapy, logopedics,
sports therapy, massage, thermal therapy).was associated with higher costs for informal care
(+4,968 EUR; p =0.03) and for outpatient physician ser-
vices (+406 EUR; p = 0.03) (Table 4). Adjusted costs for
nursing home care were not significantly different be-
tween IG and CG.
Survival, quality of life and QALY during follow-up
26 participants died in the CG, 12 died in the IG. How-
ever, deceased participants in the CG lived 331 days and
deceased participants in the IG only 310 days on aver-
age. The mean survival time was 508 days in the IG and
492 days in the CG. The mean unadjusted EQ-5D index
score decreased slightly from baseline to follow-up in
both groups, reaching 0.5563 (SD: 0.3068) in the IG and
0.5503 (SD: 0.3165) in the CG. The mean unadjusted
number of QALY during follow-up was slightly higher in
the CG (IG: 0.8256 QALY; CG: 0.8270 QALY, Table 3).
Yet, after adjustment the mean number of QALYs was
slightly, but insignificantly higher in the IG (+0.0061
QALY; p = 0.88) (Table 4).
Base case analysis
After controlling for prognostic variables via net monetary
benefit regression as described above the probability of an
ICER <50,000 EUR per QALY was only 15% for preventive
home visits. The probability of cost-effectiveness increased
with increasing WTP as shown by the CEAC (Figure 2).
At a WTP of 0 EUR per QALY the probability of cost-
effectiveness of preventive home visits was 7%, while at a
WTP of 250,000 EUR per QALY the probability was 39%.
We identified four variables that had a significant effect
on the NMB over a wide range of WTP. Higher quality of
life at baseline, less baseline limitations in instrumental ac-
tivities of daily life and less depressive symptoms led to a
higher NMB. On the other hand higher costs at baseline
resulted in a lower NMB. Yet, this effect was just marginal
and not stable under the influence of increasing WTP.
The results of the net-benefit regression at a WTP thresh-
old of 50,000 per QALY are shown in Table 5.
Sensitivity analysis
The analysis of the complete sample (n = 279) resulted
in higher adjusted costs (+10,032 EUR; p = 0.1) and
fewer adjusted QALY (−0.0074 QALY; p = 0.86) in the
IG compared to the CG. The probability of cost-
effectiveness at WTP thresholds of 0 EUR, 50,000 EUR
and 250,000 EUR per QALY was 5%, 7% and 19%,
respectively (Figure 2).
The use of the EQ VAS score resulted in fewer
adjusted QALY (−0.0166 QALY; p = 0.71) in the IG com-
pared to the CG. The probability of cost-effectiveness at
WTP thresholds of 0 EUR, 50,000 EUR and 250,000
EUR per QALY was 7%, 7% and 22%, respectively
(Figure 2).
Table 4 Adjusted* differences intervention group and control group in mean costs (by cost category) and QALY (n = 278)
Difference (Intervention – control) Bootstrapped standard error p value
Total cost [€] 4,400.52 3,019.61 0.15
Inpatient services [€] 944.82 1,088.66 0.39
Outpatient, physician services [€] 405.59 186.95 0.03**
Outpatient, non-physician services [€] −7.16 230.32 0.98
Medication [€] −60.03 220.42 0.79
Medical devices [€] −159.15 207.07 0.44
Nursing home [€] 1.15 1,227.12 0.99
Ambulatory care [€] −316.44 740.52 0.67
Informal care [€] 4,968.09 2,343.03 0.03**
Modification of buildings [€] 340.78 223.98 0.13
Transport [€] 9.01 27.45 0.74
QALY 0.0061 0.0388 0.88
*Adjusted for study region, age and gender as well as for baseline HRQL, 12-month costs at baseline, cognition, basic and instrumental abilities of daily living and
depressive symptoms by OLS regression; **p ≤ 0.05.
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index led to more adjusted QALY in the IG in compari-
son to the CG (+0.0034; p = 0.93) The probability of
cost-effectiveness at WTP thresholds of 0 EUR, 50,000
EUR and 250,000 EUR per QALY was 7%, 13% and 37%,
respectively (Figure 2).
Discussion
The purpose of our study was to perform a cost-utility
analysis of preventive home visits from a societal per-
spective in Germany. The results of our analysis showedFigure 2 Cost-effectiveness acceptability curves of the base case andthat this preventive home visit programme is unlikely to
be cost-effective. The probability of cost-effectiveness
increased with higher WTP but remained low (39% at a
threshold of 250,000 EUR per QALY). There was only a
7% chance that the preventive home visit programme is
dominant (i.e. less costly and more effective) as indicated
by the probability of cost-effectiveness at a WTP of 0
EUR per QALY. The sensitivity analysis showed that the
results were robust to the way (German EQ-5D index,
EQ VAS) QALY were calculated. The probability of
cost-effectiveness never exceeded a probability of 40%.sensitivity analyses.
Table 5 Net monetary benefit regression with WTP set at
50,000 € per QALY
Variable Coefficient p value
b (SE)
Group (ref.: control group) −4,096.59 (3,894.24) 0.29
Study center (ref.: Leipzig) −3,711.82 (5,016.88) 0.46
Group*Study Center 8,446.42 (5,904.94) 0.15
Age at baseline (centered) 623.33 (422.18) 0.14
Gender (ref.: male) 3,888.47 (3,732.30) 0.30
EQ-5D index at baseline (centered) 41,391.13 (7,215.78) 0.00**
18-month costs at baseline (centered) −0.44 (0.22) 0.04*
MMSE score at baseline (centered) 922.17 (721.08) 0.20
Barthel index score at baseline (centered) 221.85 (206.14) 0.28
IADL score at baseline (centered) 3,570.256 (1,534.46) 0.02*
GDS score at baseline (reversed, centered) 3,529.91 (1,759.86) 0.05*
Intercept 19,761.49 (4,284.06) 0.00
n = 278; bootstrapped standard errors (SE) based on 4,000 replications; R2:
0.55; GDS: Geriatric depression scale; IADL: Instrumental activities of daily
living; MMSE: Mini mental state examination; *p ≤ 0.05; **p ≤ 0.001.
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of the CEAC. The common approach is the use of the
ICER to interpret results. Yet, this approach is prone to
bias. The ICER does not control for baseline differences
between intervention and control group. Although in
our study differences between groups at baseline were
not statistically significant, even small difference may
have huge impact on the point estimate of the ICER
since costs and, in particular, QALY were very similar in
both groups during follow-up.
After adjustment for baseline differences in potential
prognostic variables, total costs during follow-up tended
to be higher in the IG than in the CG, with costs for
informal care and outpatient physician services being
significantly increased. It is possible that the preventive
home visits program has induced the participants’ de-
mand for physician services and care provided by rela-
tives and friends since the intervention explicitly aimed
at identifying care deficits and motivating participants to
seek solutions. Despite increased service use, the num-
ber of QALY was only marginally higher in the IG,
resulting in low probability for cost-effectiveness.
There is one other cost-effectiveness analysis of pre-
ventive home visits in the literature which also used
QALY as measure of health effects. Sahlen et al. reported
that preventive home visits were cost saving or cost-
effective dependent on the time horizon of the analysis
and on the inclusion or exclusion of future health care
costs in life years gained [11].
Two differences between our study and the study of
Sahlen et al. should be considered. The first difference is
the implementation of the intervention. Sahlen et al.performed two home visits per year over two years. In
our study three visits in seven weeks were performed. It
is possible that frequent visits over a longer time period
are economically superior to a short term approach
trying to give a stimulus for changes in behaviour and
living environment. However, a study by Melis et al.
showed that this is not necessarily the case [12]. This re-
search group analysed a preventive home visit programme
which performed a maximum of six visits over three
months. The intervention was cost effective in terms of
cost per successful treatment (prevented functional de-
cline accompanied by improved mental well-being). The
second difference is the age of the population and associ-
ated with this the choice of the effect measure. The sam-
ple of the study by Sahlen et al. had a mean age of
79.8 years [11] whereas the mean age in our sample was
84.8 years. We observed a decrease in quality of life be-
tween the baseline and the follow-up assessment in both
groups which seems to be an age-related phenomenon. In
the study by Sahlen et al. the HRQL measured with the
EQ-5D index was higher (0.7) and assumed as stable over
time.
There was only one statistically significant effect in
our study. The number of deceased patients was lower
in the IG than in the CG. In another analysis of their
data, Sahlen et al. reported similar results [50]. They
found that the risk of death decreased to 2.7% in the
intervention group as compared to 4.8% in the control
group. In our case the difference was larger (IG: 9% risk;
CG: 18% risk) but this can be explained by the higher
age of the population. Whether this effect is caused by
the intervention should be evaluated by further research
employing a longer time horizon and including more
patients.
The main limiting factor of our study is the fact that
there was only a non-significant reduction of nursing
home admissions. Therefore the primary analysis failed
to show effectiveness of the intervention. The reason for
this is that a higher number of nursing home admissions
was expected when planning the study. Eventually, a risk
reduction of 45% was identified which was not statisti-
cally significant though. It is reasonable to assume that
there is a chance to reach statistical significance for this
relevant difference with a larger sample size. The added
value of the present analysis is that we used a standard
health economic measure of effectiveness (QALY) for
which we found only a very small difference. By increas-
ing the sample size to possibly reach statistical signifi-
cance for the primary outcome the interpretation of the
findings of our economic evaluation would probably not
change substantially. The intervention would still be
likely to have a pronounced and negative net-monetary
benefit resulting from notable incremental costs and
very small incremental QALY. This means that even if
Brettschneider et al. BMC Health Services Research  (2015) 15:141 Page 10 of 11the intervention turned out to be effective based on the
primary outcome it would not be likely to be cost-
effective.
The following limitations should be considered in
interpreting our findings. First of all, our sample may
not be representative of the older population at high risk
for admission to a nursing home in the two regions. We
used a non-random sampling approach recruiting pa-
tients at baseline consecutively from GP practices, hospi-
tals and the registration office in the two centres.
However, 93% of people aged 70+ are regularly seen by a
GP, which supports the representativeness of our popu-
lation [51]. All consecutive patients were asked to par-
ticipate in the study. However, some selection bias
towards patients more willing and able to participate
cannot be ruled out completely. Secondly, sample size
might have been not sufficient enough to detect differ-
ences in outcomes. Sample size calculations were based
on the number of prevented nursing home admissions,
the primary outcome of the effectiveness study. Thirdly,
we only observed our variables at baseline and one
follow-up, reducing the ability to track more precisely
health-related quality of life and costs over time. There-
fore estimates in health status and costs more reflect the
situation at 18 months rather than the health status and
services used shortly after the intervention.
Conclusion
The evaluated preventive home visits program is unlikely
to be cost-effective. In the development of future pro-
grams aspects like the duration of the program, fre-
quency of visits and the age of the target group should
be considered.
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